Kandace Linkous
About Kandace Linkous
Kandace Linkous is a scientist at the Vaccine Production Program Laboratory within the Vaccine Research Center at the National Institute of Allergy and Infectious Diseases. She has over a decade of experience in developing monoclonal antibodies, virus-like particles, and nanoparticles.
Work at National Institutes of Health
Kandace Linkous has been employed as a Scientist at the National Institutes of Health (NIH) since 2014. She works within the Vaccine Production Program Laboratory (VPPL) at the Vaccine Research Center (VRC), which is part of the National Institute of Allergy and Infectious Diseases (NIAID). In her role, she serves as a project manager and liaison for technology transfer and qualification activities, contributing to the advancement of vaccine research and development.
Education and Expertise
Kandace Linkous earned her Bachelor's degree in Biochemistry and Chemistry from Virginia Tech, where she studied from 2000 to 2005. She later pursued a Master's degree in Biotechnology and Management at the University of Maryland Global Campus, completing her studies from 2010 to 2012. Her educational background supports her extensive experience in developing and characterizing monoclonal antibodies (mAbs), virus-like particles (VLPs), and nanoparticles.
Previous Work Experience
Before her current position at NIH, Kandace Linkous worked at Medimmune in various roles. She served as an Associate Scientist in Analytical Biotech Development and Physiochemical Methods from 2013 to 2014, and as an Associate Scientist in Analytical Biochemistry and Development from 2008 to 2013. Additionally, she worked as a Technical Specialist at Senseonics, Incorporated from 2005 to 2007. These roles provided her with a solid foundation in analytical techniques and biotechnological applications.
Professional Contributions
Throughout her career, Kandace Linkous has focused on the development and characterization of advanced biotechnological products. Her work with monoclonal antibodies, virus-like particles, and nanoparticles has contributed to the field of vaccine research. Her role as a project manager and liaison at NIH further emphasizes her commitment to facilitating technology transfer and ensuring the qualification of new technologies in vaccine production.